Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.61 USD
Change Today +0.01 / 0.63%
Volume 6.8K
VYCO On Other Exchanges
Symbol
Exchange
OTC US
As of 12:43 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

vycor medical inc (VYCO) Snapshot

Open
$1.58
Previous Close
$1.60
Day High
$1.65
Day Low
$1.58
52 Week High
09/4/14 - $2.65
52 Week Low
07/8/15 - $0.91
Market Cap
17.5M
Average Volume 10 Days
13.4K
EPS TTM
$-0.25
Shares Outstanding
10.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VYCOR MEDICAL INC (VYCO)

Related News

No related news articles were found.

vycor medical inc (VYCO) Related Businessweek News

No Related Businessweek News Found

vycor medical inc (VYCO) Details

Vycor Medical Inc. designs, develops, and markets neurological medical devices and therapies in the United States and internationally. The company also develops non-invasive, computer-based therapies for those suffering from vision loss resulting from neurological trauma. It operates in two segments, Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a suite of clear cylindrical minimally invasive disposable devices for brain surgeries. It has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe, Korea, and Japan; and is seeking or has partial regulatory approvals in India, Russia, Taiwan, and Vietnam. The NovaVision segment develops and provides science-driven neurostimulation therapy and other medical technologies that help enhance and partially restore sight in patients with neurological vision impairments. It offers proprietary Visual Restoration Therapy platform, which is clinically supported to enhance lost vision resulting from stroke, traumatic brain injury, or other acquired brain injuries; and Neuro Eye Therapy in the European Union for enhancing visual sensitivity deep within the field defect. This segment also provides NeuroEyeCoach, a saccadic training software that re-trains the ability of a patient to move their eyes, and re-integrate left and right vision; and NovaVision VIDIT, a diagnostic system that enables therapists in rehabilitation centers and other clinics to perform high-resolution visual field tests to screen for central visual field deficits associated with stroke or brain injury. The company primarily serves patients, hospitals, and medical professionals. Vycor Medical, Inc. sells its products directly to hospitals through independent representatives, as well as through various distributors. The company was founded in 2005 and is headquartered in Boca Raton, Florida.

14 Employees
Last Reported Date: 08/14/15
Founded in 2005

vycor medical inc (VYCO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: --
President and Director
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

vycor medical inc (VYCO) Key Developments

Vycor Medical Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015

Vycor Medical Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $286,018, operating loss of $458,093, loss before provision for income taxes of $420,267, net loss of $420,267, net loss available to common shareholders of $420,267 or $0.04 per basic and diluted share, non-GAAP operating loss of $349,165, non-GAAP net loss of $361,006 or $0.03 per basic and diluted share compared to the revenue of $298,540, operating loss of $703,608, loss before provision for income taxes of $1,278,385, net loss of $1,278,385, net loss available to common shareholders of $1,278,385 or $0.12 per basic and diluted share, non-GAAP operating loss of $416,755, non-GAAP net loss of $462,695 or $0.04 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported revenue of $614,570, operating loss of $1,066,411, loss before provision for income taxes of $1,144,448, net loss of $1,144,448, net loss available to common shareholders of $1,266,894 or $0.11 per basic and diluted share, non-GAAP operating loss of $810,714, non-GAAP net loss of $834,396 or $0.08 per basic and diluted share compared to the revenue of $656,662, operating loss of $1,696,146, loss before provision for income taxes of $2,066,395, net loss of $2,066,395, net loss available to common shareholders of $2,066,395 or $0.21 per basic and diluted share, non-GAAP operating loss of $737,483, non-GAAP net loss of $831,546 or $0.08 per basic and diluted share for the same period a year ago.

Vycor Medical, Inc. Announces Commercial Release of its NovaVision Web Deliverable Therapy Suite

Vycor Medical Inc. announced the commercial release of its Internet-delivered therapy suite in the U.S. This therapy suite, consisting of its lead Vision Restoration Therapy (VRT) and its NeuroEyeCoach eye-movement compensation therapy, is delivered directly to patients over the Internet onto their own computers replacing the Company's current 'prototype hardware centric' model. NovaVision has been working to take its VRT therapy prototype and develop it into an affordable, scalable therapy offering that offers broader patient benefits. VRT will going forward be provided alongside NovaVision's NeuroEyeCoach compensatory therapy in one Internet delivered therapy suite. Two things happen when someone suffers from vision related disorders following a stroke or brain injury: there is a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT addresses the restoration of lost vision while NeuroEyeCoach addresses patients' difficulty with their eye movements and their ability to integrate visual information, allowing them to make the most of their remaining vision, The two therapies provided in a suite are therefore highly complementary and ensure broad benefits to NovaVision's patients. NovaVision is now positioned, for the first time, with the suite of therapies and product offerings to deliver on its strategic vision: to provide a clinically supported, affordable and scalable visual therapy solution offering broad benefits to those suffering visual impairment following neurological damage; and to offer solutions for both patients and physicians alike. NovaVision will commercially launch this week these two complementary therapies, internet-delivered in a package for $900.

Vycor Medical Inc. Signs Agreement with HealthSouth for Second NovaVision Therapy Product

Vycor Medical Inc. announced that it has entered into an agreement with HealthSouth Corporation (HLS) to make available its NeuroEyeCoach Professional Center therapy program to participating HealthSouth hospitals, following a 3-month trial of the therapy in two HealthSouth locations. NeuroEyeCoach is NovaVision's eye movement compensation therapy for those patients who have suffered a cerebral visual field disorder as a result of a stroke or brain injury and is designed to improve a patient's ability to scan their environment more efficiently. The program is based on several decades of scientific research pioneered by Professor Josef Zihl at the Max Planck Institute in Munich that has been the subject of numerous clinical studies. Participating HealthSouth hospitals will use the program to treat patients while in their care. In contrast to other clinic-based saccadic programs, NeuroEyeCoach is a full-course therapy dedicated to cerebral visual field disorders and can be continued by the patient in their home environment. This agreement follows the approval by HealthSouth in late 2014 to make available its VIDIT diagnostic to their hospital network and NovaVision is installing devices into this network. The NovaVision VIDIT is the diagnostic component of the Company's Vision Restoration Therapy (VRT) and is used to perform high-resolution visual field tests to screen for central visual field deficits commonly associated with stroke or brain injury. The ability for Health South physicians to be able to quickly identify visual disorders through the effective screening program is highlighted by the fact that approximately one-third of stroke or other brain injury patients suffer from a neurologically induced visual disorder and if this deficit goes undetected it may adversely impact other rehabilitation modalities. Early detection and treatment are critical steps towards improving overall patient care, a key objective of HealthSouth. Once diagnosed, patients are able to be treated in-clinic with NeuroEyeCoach and referred to NovaVision for treatment following discharge at home using VRT, which is the only FDA cleared clinically supported therapy targeted at the restoration of lost vision resulting from neurological brain damage such as that resulting from stroke.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VYCO:US $1.61 USD +0.01

VYCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardinal Health Inc $80.97 USD +0.74
Integra LifeSciences Holdings Corp $59.49 USD +1.14
View Industry Companies
 

Industry Analysis

VYCO

Industry Average

Valuation VYCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.3x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VYCOR MEDICAL INC, please visit www.vycormedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.